Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...

As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

The global kinase inhibitor in autoimmune diseases market is projected to grow steadily over the next decade, according to a ...

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

The projected annual revenue for Gilead Sciences is 26,909MM ... first therapies to the market. Through global partnerships, Gilead's medicines today reach millions of people in low- and middle ...

The 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a ...

PORTLAND, CA, UNITED STATES, October 7, 2024 /EINPresswire / -- According to the report, the global cancer gene therapy <a target=_blank href=ht ...

According to Gilead Sciences, the data from the two trials will now be used to support a series of global regulatory filings ... needs to be in place to reach at-risk populations and make sure ...

With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, ...